

Perspective

ACNP White Paper: Update on Use of Antipsychotic Drugs in Elderly Persons with Dementia

Dilip V Jeste^{*,1,2}, Dan Blazer³, Daniel Casey⁴, Thomas Meeks¹, Carl Salzman⁵, Lon Schneider⁶, Pierre Tariot⁷ and Kristine Yaffe⁸

¹Department of Psychiatry and Neurosciences, University of California, San Diego, CA, USA; ²VA San Diego Healthcare System, University of California, San Diego, CA, USA; ³Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA;

⁴Department of Psychiatry and Neurology, Oregon Health and Science University, Portland, OR, USA; ⁵Department of Psychiatry, Massachusetts Mental Health Center, Jamaica Plain, MA, USA; ⁶Department of Psychiatry, Neurology, and Gerontology, University of Southern California, Los Angeles, CA, USA; ⁷Department of Psychiatry, Medicine, Neurology, and Aging/Developmental Biology, University of Rochester, Rochester, NY, USA; ⁸Department of Psychiatry, Neurology, and Epidemiology/Biostatistics, University of California, San Francisco, CA, USA

In elderly persons, antipsychotic drugs are clinically prescribed off-label for a number of disorders outside of their Food and Drug Administration (FDA)-approved indications (schizophrenia and bipolar disorder). The largest number of antipsychotic prescriptions in older adults is for behavioral disturbances associated with dementia. In April 2005, the FDA, based on a meta-analysis of 17 double-blind randomized placebo-controlled trials among elderly people with dementia, determined that atypical antipsychotics were associated with a significantly (1.6–1.7 times) greater mortality risk compared with placebo, and asked that drug manufacturers add a 'black box' warning to prescribing information for these drugs. Most deaths were due to either cardiac or infectious causes, the two most common immediate causes of death in dementia in general. Clinicians, patients, and caregivers are left with unclear choices of treatment for dementia patients with psychosis and/or severe agitation. Not only are psychosis and agitation common in persons with dementia but they also frequently cause considerable caregiver distress and hasten institutionalization of patients. At the same time, there is a paucity of evidence-based treatment alternatives to antipsychotics for this population. Thus, there is insufficient evidence to suggest that psychotropics other than antipsychotics represent an overall effective and safe, let alone better, treatment choice for psychosis or agitation in dementia; currently no such treatment has been approved by the FDA for these symptoms. Similarly, the data on the efficacy of specific psychosocial treatments in patients with dementia are limited and inconclusive. The goal of this White Paper is to review relevant issues and make clinical and research recommendations regarding the treatment of elderly dementia patients with psychosis and/or agitation. The role of shared decision making and caution in using pharmacotherapy for these patients is stressed.

Neuropsychopharmacology advance online publication, 18 July 2007; doi:10.1038/sj.npp.1301492

Keywords: antipsychotic drugs; dementia; mortality; psychosis; stroke

BACKGROUND: PSYCHOSIS AND AGITATION IN DEMENTIA PATIENTS

Among US adults over age 65, prevalence estimates of dementia range from 5 to 15%, with Alzheimer's Disease (AD) being the most common type of dementia (Kaplan and Sadock, 1998; Evans *et al*, 1989; Losonczy *et al*, 1998). A recent review estimated that worldwide 24 million people have dementia, and that this number will double by the year 2020 (Ferri *et al*, 2005).

Behavioral and psychiatric symptoms develop in as many as 60% of community-dwelling dementia patients (Wragg

and Jeste, 1988; Lyketsos *et al*, 2000) and in more than 80% of patients with dementia living in nursing homes (Testad *et al*, 2007; Zuidema *et al*, 2006); the lifetime risk of such complications approaches 100% (Lyketsos *et al*, 2000). Psychosis of AD is characterized by delusions or hallucinations (Jeste and Finkel, 2000). The reported prevalence of delusions in AD patients ranges from 9 to 63% (median 36%), and that for hallucinations from 4 to 41% (median 18%) (Ropacki and Jeste, 2005). Rates of physical aggression among community-dwelling dementia patients range from 11 to 46%, whereas rates from institutional settings range from 31 to 42% (Brodsky and Low, 2003). The range of prevalence estimates for agitation in dementia is even wider—from 20 to over 80% (Tractenberg *et al*, 2003; Ryu *et al*, 2005). Agitation may be conceptualized as a single symptom or a symptom complex, and may co-occur with psychosis or depression (Jeste *et al*, 2006).

*Correspondence: Dr DV Jeste, VA San Diego Healthcare Services, University of California, San Diego, 3350 La Jolla Village Drive, Building 13, 4th Floor, San Diego, CA 92161, USA, Tel: +858 534 4020, Fax: +858 552 7404, E-mail: djeste@ucsd.edu

Received 13 March 2007; revised 21 May 2007; accepted 24 May 2007

Neuropsychiatric symptoms frequently have several adverse clinical repercussions. Psychosis and agitation in patients with dementia decrease quality of life (Matsui *et al*, 2006; Banerjee *et al*, 2006) and may portend a worse prognosis. Several studies indicate that psychosis is associated with more rapid cognitive decline among persons with dementia (Drevets and Rubin, 1989; Rosen and Zubenko, 1991; Wilson *et al*, 2006). Some evidence suggests that agitation and/or psychosis in dementia might be associated with increased mortality, although this finding has been inconsistent. Walsh *et al* (1990) demonstrated that behavioral disturbances in general (relative risk 1.5, 95% CI 1.0–2.5), and wandering combined with falls in particular (relative risk 3.1, 95% CI 1.4–6.6) were associated with decreased survival over 6+ years of follow-up, although on multivariate analysis, these relative risks failed to reach significance. One study found that nursing home residents who later died had displayed more verbal agitation than those who survived during the same follow-up period ($t=2.03$, effect size 0.51) (Allen *et al*, 2005); however, another study reported that the association between mortality and agitation in dementia disappeared on multivariate analysis (Bowen *et al*, 1996). Likewise, some investigations have demonstrated an association between psychosis of dementia and increased mortality (Wilson *et al*, 2006), whereas other researchers have not found such a relationship (Samson *et al*, 1996; Rosen and Zubenko, 1991).

Psychosis and agitation in patients with different types of dementias have been consistently associated with increased caregiver distress (Kaufer *et al*, 1998; Fuh *et al*, 2001; Donaldson *et al*, 1998; Aarsland *et al*, 2007; Mourik *et al*, 2004). The myriad of adverse psychological and physical consequences of caregiver stress has been reviewed (Pinquart and Sorensen, 2003). One reported association of caregiver distress is early patient institutionalization. In a large prospective study, both caregiver burden and behavioral symptoms were independently associated with nursing home placement of persons with dementia (Yaffe *et al*, 2002). Forty-six percent of caregivers in another study reported behavioral problems as a reason for the decision to place persons with dementia outside the home, and caregiver stress was higher among persons opting for nursing home placement (Buhr *et al*, 2006). A combination of the various adverse effects of neuropsychiatric symptoms in dementia likely leads to increased system-wide health-care costs (Murman and Colenda, 2005).

Summary

Psychosis and agitation are not only common but also have serious clinical consequences in persons with dementia.

EFFICACY OF ANTIPSYCHOTICS IN DEMENTIA PATIENTS

Historical Background

With the discovery of the first dopamine-blocking typical (or conventional or first-generation) antipsychotic chlorpromazine in 1952, a revolution in psychiatric therapeutics occurred that radically changed the treatment of schizophrenia and other severe mental illnesses. Over the subsequent

decades, adverse long-term consequences of these antipsychotic agents, especially tardive dyskinesia, became evident, but effective and safe therapeutic alternatives did not exist. With the advent of clozapine (Food and Drug Administration (FDA) approval in 1989) followed by other atypical (or second-generation) antipsychotics (risperidone in 1993, olanzapine in 1996, quetiapine in 1997, ziprasidone in 2001, and aripiprazole in 2002), therapeutic options for psychosis expanded. Atypical antipsychotics demonstrated significantly lower risks of motor side effects and somewhat better overall tolerability compared with the typical agents (Glazer, 2000; Jeste *et al*, 1999a; Ritsner *et al*, 2004; Stanniland and Taylor, 2000). The atypical antipsychotics came to be used widely in different patient populations, including older adults with dementia, who were especially susceptible to the motor side effects of the typical agents (Jeste, 2000). However, based primarily on studies conducted in younger adult populations, the newer agents eventually proved to have their own liabilities, mainly in terms of metabolic side effects (eg weight gain, type-II diabetes mellitus, and dyslipidemia) (Jin *et al*, 2004). In addition, studies have called into question the degree to which atypical antipsychotics (excluding clozapine) represent a significant advance in therapeutic effectiveness compared with the typical agents in schizophrenia (Lieberman *et al*, 2005; Jones *et al*, 2006).

Trials of Antipsychotics in Dementia

Approximately half of the clinical trials of antipsychotics in dementia patients recruited individuals with psychosis, whereas the other half selected individuals with agitation or global behavioral disturbance. Yet, most trials of psychosis did not exclude agitation, and vice versa, resulting in many trials including persons with elevated symptom scores for both psychosis and agitation (Schneider *et al*, 2006a).

Psychosis

Overall, atypical antipsychotic drugs appear to have modest efficacy for treating the psychosis of AD (Ballard and Waite, 2006; Sink *et al*, 2005), although studies have not always found significant advantage over placebo in terms of psychotic symptoms (Kindermann *et al*, 2002; Schneider *et al*, 2006a). Schneider *et al* (2006a) reviewed 15 randomized controlled trials (RCTs) of atypical antipsychotics for agitation and/or psychosis of dementia that predated the CATIE-AD trial (three with aripiprazole, four with olanzapine, four with risperidone, one comparing olanzapine and risperidone, and three with quetiapine). Eleven trials were conducted in nursing homes and four in outpatient settings. A vast majority of subjects included had AD (87%), and were women (70%) with a mean age of 81 years. Overall, in these trials, it is somewhat difficult to disentangle the efficacy of antipsychotics for psychosis from their efficacy for global neuropsychiatric disturbance or for agitation. Several trials included patients with heterogenous mixtures of psychosis and agitation. The trials used a variety of outcome measures, and when primary outcome measures were reported, they often represented a global measure of neuropsychiatric symptoms. Combining data for individual drugs, psychosis scores improved significantly only in trials of risperidone. On the other hand, global

neuropsychiatric symptoms improved with active treatment in pooled analysis of aripiprazole and risperidone. In the six studies that assessed operationally defined psychosis of AD, there was no significant effect in any of the trials on psychosis rating scales. Subgroup analysis revealed better overall response in patients without (*vs* with) psychosis, those in nursing home (*vs* outpatient) settings, and those with severe (*vs* moderate) cognitive impairment.

In the CATIE-AD trial, the largest ($N=421$) non-industry sponsored study of atypical antipsychotics for psychosis or agitation/aggression in people with dementia, olanzapine, quetiapine, and risperidone were no better than placebo for the primary outcome (time to discontinuation for any reason) or the secondary outcome (Clinical Global Impression or CGI) (Schneider *et al*, 2006b). Time to discontinuation due to lack of efficacy favored olanzapine and risperidone, whereas time to discontinuation due to adverse events favored placebo. The CATIE-AD outcome measures were selected to assess effectiveness by focusing on more clinically meaningful or relevant outcomes, in contrast to many previous trials, which used psychopathologic rating scales such as the Neuro-Psychiatric Inventory (NPI), Brief Psychiatric Rating Scale (BPRS), and BEHAVE-AD to assess efficacy (Bech *et al*, 1988; Reisberg *et al*, 1996; Cummings, 1997). The CATIE-AD trial was, however, not without limitations. The authors have noted such issues as possible underdosing of antipsychotics (especially regarding quetiapine) and the relatively high discontinuation rates compared with previous efficacy trials (Schneider *et al*, 2006a; Schneider *et al*, 2007). Although the design of CATIE-AD might have led to elevated rates of treatment discontinuation (eg through relatively quick decisions to stop therapy and move on to phase 2 of the study), this may also reflect real-world clinical decision-making as it was more of an effectiveness than an efficacy study. Finally, CATIE-AD was conducted with outpatients, a group noted above to demonstrate possibly less response to atypical antipsychotics than nursing home residents or more cognitively impaired patients.

Efficacy data reported as 'Number Needed to Treat' (NNT), the number of patients that need to receive a given therapy in order to successfully treat one person, may be especially meaningful for clinicians. In a meta-analysis of large-scale RCTs of atypical antipsychotics in dementia, the NNT ranged from 5 to 14, depending on the outcome measure, the criterion for improvement, and methodology used (Schneider *et al*, 2006a). The overall average treatment effect was about 18%, a figure remarkably similar to that found in a meta-analysis of studies of conventional antipsychotics in this population (Schneider *et al*, 1990).

Agitation

Only a few studies of antipsychotics specifically targeted agitation or aggression. It is noteworthy that, as mentioned before, Schneider *et al* (2006a) reported better response in trials of atypical antipsychotics for dementia patients without (*vs* with) psychosis; thus, patients with agitation alone may preferentially respond to these medications (although common comorbidities such as depression and anxiety were not fully characterized in these patients with agitation). In another meta-analysis, Lonergan *et al* (2001) found that haloperidol was beneficial for dementia patients

with aggression, but not for general agitation (ie wandering, verbal agitation, etc). Similarly, in recent trials, no significant therapeutic effects were found for haloperidol compared with placebo and trazodone (Teri *et al*, 2000), compared with placebo and quetiapine (Tariot *et al*, 2006), and compared with risperidone and placebo (De Deyn *et al*, 1999). Some, although not all, RCTs with risperidone, olanzapine, and aripiprazole have shown modest efficacy for reducing aggression and overall agitation in AD (Ballard and Waite, 2006; Sink *et al*, 2005).

Comparisons with Typical Antipsychotics

Because of the recent black-box warnings about strokes and mortality with atypical antipsychotics (see below), some clinicians have begun to switch to the older typical antipsychotic agents. However, there have been only four RCTs comparing these two classes of antipsychotics in persons with dementia: three comparing risperidone with haloperidol (Chan *et al*, 2001; De Deyn *et al*, 1999; Suh *et al*, 2004), and one comparing quetiapine and haloperidol (Tariot *et al*, 2006). Only one of the four trials found a significantly greater efficacy with the atypical than with the typical agent; the others found no significant difference in this respect. However, in all four studies, haloperidol was associated with more EPS than the atypical agent. Atypical antipsychotics are less likely than most typical antipsychotics (especially haloperidol) to cause or exacerbate EPS and tardive dyskinesia in dementia patients but no other advantages in terms of efficacy or safety have been demonstrated. Likewise, the typical antipsychotics have no proven therapeutic advantages over atypical agents, but typical drugs are less expensive, and individual typical drugs may have less propensity to cause certain side effects (eg anticholinergic, hypotensive, metabolic) compared with certain individual atypical agents.

Despite the lack of an FDA-approved indication, the largest number of atypical antipsychotic prescriptions in older adults is for behavioral disturbances in persons with dementia (Weiss *et al*, 2000). This suggests a need for designing and conducting further clinical trials of appropriate medications for dementia-associated psychosis and/or agitation. Although advances in defining phenotypes of psychosis in dementia have been made (eg operationalized criteria for psychosis (Jeste and Finkel, 2000)), these were not used in early clinical trials. Careful consideration must also be given to the validity of outcome measures used for psychosis and other neuropsychiatric symptoms, such as how these may relate to clinically meaningful outcomes.

Summary

The RCTs examining antipsychotics for psychosis and/or agitation associated with dementia, in aggregate, suggest modest efficacy in symptom reduction with active treatment compared with placebo. However, several individual trials have yielded negative results.

ADVERSE EFFECTS OF ANTIPSYCHOTICS IN DEMENTIA PATIENTS

During the past decade, atypical antipsychotics have largely replaced typical agents in the treatment of psychosis,

aggression, and agitation in patients with dementia because of perceived greater tolerability and lesser risk for acute EPS, and because of the documented lower risk for tardive dyskinesia compared with typical agents (Glazer, 2000; Dolder and Jeste, 2003; Jeste *et al*, 1999a; Ritsner *et al*, 2004; Stanniland and Taylor, 2000). On the other hand, most of these drugs have other acute and subacute side effects in elderly persons such as sedation, postural hypotension, and falls, especially at higher doses. There have been no large-scale published studies of antipsychotic-associated diabetes, obesity, and dyslipidemia among elderly dementia patients. However, during the last 3 years, two serious adverse events have been associated with the use of atypical antipsychotics in dementia patients, resulting in black-box warnings by the FDA: cerebrovascular adverse events (CVAEs) and death.

Cerebrovascular Adverse Events

In 2003, the FDA issued a warning titled 'Cerebrovascular Adverse Events, Including Stroke, in Elderly Patients with Dementia'. It referred to CVAEs (eg stroke, transient ischemic attack), including fatalities, reported in patients (mean age 85 years; age range 73–97) in trials of risperidone in elderly patients with dementia-related psychosis and/or agitation. In placebo-controlled trials, there was a significantly higher incidence of CVAEs in patients treated with risperidone compared with those treated with placebo. In 2003, Janssen (manufacturer of risperidone), in consultation with the FDA, added the following warning to risperidone prescribing information regarding stroke risk in older dementia patients.

'Combining data from all the 3 published large-scale double-blind placebo-controlled trials of risperidone, (De Deyn *et al*, 1999; Katz *et al*, 1999; Brodaty *et al*, 2003) 12 out of 744 patients on risperidone compared to 4 out of 562 on placebo developed serious cerebrovascular events. Of these patients, 4 on risperidone and 2 on placebo died. At this time, no cause-and-effect relationship can be established between risperidone and strokes; nonetheless, such a possibility cannot be ruled out.'

Combining data from three published placebo-controlled RCTs of risperidone with those from three unpublished trials, Janssen reported the rates of risperidone- vs placebo-associated serious CVAEs were not significantly different ($15/1009 = 1.5\%$ for risperidone vs $4/712 = 0.6\%$ for placebo, $p = 0.27$). However, using the same data, risperidone-treated patients had significantly higher rates of non-serious CVAEs than placebo-treated patients ($18/1009 = 1.8\%$ and $4/712 = 0.6\%$, respectively; $p = 0.026$) (Herrmann and Lanctot, 2005).

Soon thereafter, a similar warning was applied to olanzapine and aripiprazole. In the five olanzapine trials, the relative risk of CVAEs was 1.8 (95% CI 0.5, 6.3), which was not statistically significant ($p = 0.36$). Collectively, the 11 risperidone/olanzapine studies suggested that 48 of 2187 (2.2%) drug-treated subjects experienced CVAEs compared with 10 of 1190 (0.8%) placebo-treated subjects (Herrmann and Lanctot, 2005); the combined relative risk

was 2.7 (95% CI 1.4, 5.3). In placebo-controlled trials with aripiprazole in psychosis of AD (two flexible dose trials and one fixed dose study), there was an increased incidence of CVAEs (eg stroke, transient ischemic attack), including fatalities, in aripiprazole-treated patients (mean age: 84 years; range: 78–88 years) (Abilify prescribing information, 2006). The relative risk of CVAEs is not directly reported in the prescribing information for aripiprazole. In the fixed-dose study, there was a statistically significant dose-response relationship for CVAEs in patients treated with aripiprazole. Analysis of data combined from two studies of quetiapine vs placebo in dementia yielded rates of CVAE's of 0.9 vs 1.9%, respectively (relative risk 0.5, 95% CI 0.1–2.0) (Schneider LS, Tariot PN, Mintzer J *et al*, unpublished). However, the data with quetiapine in dementia patients are somewhat more limited than those with risperidone, olanzapine, or aripiprazole. A meta-analysis found that pooled rates of CVAEs were 1.9% in atypical antipsychotic-treated patients vs 0.9% in placebo-treated patients, yielding an odds ratio of 2.1 (95% CI 1.2, 3.8) (Schneider *et al*, 2006a).

Limitations of CVAE data. The increased risk for CVAEs was determined from RCTs, and is based on unbiased estimates. However, interpretation of the risk is limited by several facts including the following:

- (a) These studies were designed and powered to determine efficacy, not a cause-and-effect relationship between atypical antipsychotics and CVAEs.
- (b) The category of serious CVAEs was broad and not operationally defined while designing the trials. The diagnoses of serious CVAEs were based on spontaneously reported adverse events; these were not validated. Nevertheless, whatever the events were, they were being determined in an unbiased manner in double-blind, placebo-controlled trials, and occurred more frequently with atypical antipsychotics than with placebo. It is thus possible that some of the actual events could have been characterized as non-'cerebrovascular' in origin, although this does not mitigate concern about their seriousness.
- (c) Typical vs atypical antipsychotics: Gill *et al* (2005) in a retrospective cohort study reported that, after adjustment for potential confounders, participants receiving atypical antipsychotics showed no significant increase in the risk of ischemic stroke compared with those receiving typical antipsychotics (adjusted hazard ratio 1.0, 95% CI 0.8, 1.3). This finding was consistent in subgroup analyses of individual atypical antipsychotic drugs (risperidone, olanzapine, and quetiapine) and selected subpopulations of the total sample. This was similar to the results reported by other authors (Herrmann *et al*, 2004) that typical antipsychotics appeared similar to atypical agents in stroke risk. However, the retrospective databases used for these analyses were not intended to address the issue of CVAEs with antipsychotics. Among the four previously described RCTs comparing typical vs atypical antipsychotics, none reported a differential incidence of CVAEs with typical or atypical antipsychotics, although sample sizes were smaller than might be needed to demonstrate

such differences (Chan *et al*, 2001; De Deyn *et al*, 1999; Suh *et al*, 2004).

Possible mechanisms. Mechanisms underlying antipsychotic-associated CVAEs are unknown. It is conceivable that such mechanisms could be somewhat different for different drugs. Hypotheses could include: orthostatic hypotension (α_1 -receptor blockade); tachycardia (α_1 - and M_2 -receptor blockade); metabolic derangements due to atypical antipsychotics such as insulin resistance, weight gain, dyslipidemia (possibly due to H_1 -, M_3 -, $5HT_2$ -receptor blockade); sedation (eg D_2 -, $5HT_2$ -, H_1 -receptor blockade) and/or EPS (D_2 -receptor blockade) leading to venous stasis and consequent activation of pro-coagulant pathways; and hyperprolactinemia (D_2 -receptor blockade), which has been associated with impaired endothelial function, decreased insulin-sensitivity, and increased platelet aggregation (Herrmann and Lanctot, 2005). All of the above-mentioned mechanisms are speculative, and not shown to be causally related to CVAEs with antipsychotics. The relationship of antipsychotic dose or drug–drug interactions to CVAEs is unclear.

Mortality

The FDA issued the following warning in May 2004 for all atypical antipsychotics based on their examination of published and unpublished proprietary clinical trials data:

‘Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks) in these patients revealed a risk of death in the drug-treated patients of between 1.6 to 1.7 times that seen in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (eg heart failure, sudden death) or infectious (eg pneumonia) in nature. These drugs are not approved for the treatment of patients with dementia-related psychosis.’

A meta-analysis of 15 RCTs documented the risk of mortality with atypical antipsychotics compared with placebo as 3.5 *vs* 2.3%, respectively (OR 1.5; 95% CI 1.1, 2.2) (Schneider *et al*, 2005). Using the concept of ‘Number Needed to Harm’ (NNH), similar to NNT, for every 100 (95% CI 53, 1000) dementia patients treated with an atypical antipsychotic over 10–12 weeks, there would be one death due to atypical drug use. Given the above-mentioned NNT calculations, the likelihood of benefit *vs* serious risk would be modest: for every nine to 25 persons helped with these medications, there would be one death.

Limitations of mortality data. As with the CVAEs, there are important limitations to the above-mentioned data on mortality in the published RCTs.

(a) Insufficient information is available on individual cases, causes or circumstances of death, baseline clinical

characteristics, medical conditions, and concurrent medications. Most deaths were due to either cardiac or infectious disorders, which are also the two most common immediate causes of death in patients with dementia in general (Keene *et al*, 2001; Kammoun *et al*, 2000).

(b) **Typical *vs* atypical antipsychotics:** a meta-analysis noted that, in two RCTs including haloperidol, the increased risk of death in dementia patients treated with haloperidol relative to placebo (OR 1.7, 95% CI 0.7–3.9) was similar to the average increase in risk reported with atypical drugs relative to placebo (Schneider *et al*, 2005). Cerebrovascular adverse events and quetiapine: a pooled analysis in elderly patients with dementia. Presented at the 18th Annual Meeting of the American Association for Geriatric Psychiatry, San Diego, CA, March 3–6). Although the difference in mortality rates between haloperidol and placebo was not statistically significant, this does not equate to a lack of concern. In a recent paper, Wang *et al* (2005) reported the results of a retrospective cohort study of mortality involving 22 890 patients, 65 years of age or older, treated with antipsychotics. Typical antipsychotic medications were associated with a significantly higher adjusted risk of death than were atypical antipsychotic medications at all intervals studied (≤ 180 days: relative risk, 1.4; 95% CI, 1.3–1.5; < 40 days: relative risk, 1.6; 95% CI, 1.4–1.8; 40–79 days: relative risk, 1.4; 95% CI, 1.2–1.6; and 80–180 days: relative risk, 1.3; 95% CI, 1.1–1.4), and in all subgroups defined according to the presence or absence of dementia or nursing home residency. Similar results (ie higher mortality with typical than with atypical antipsychotics among older adults) were reported in two other retrospective analyses of large health system databases (Nasrallah *et al*, 2004; Schneeweiss *et al*, 2007). A Finnish study of 254 frail elderly patients with dementia in nursing homes and hospitals found no increase in mortality with either typical or atypical antipsychotics over a 2-year period (Raivio *et al*, 2007). These studies have the usual limitations that accompany retrospective data analyses, and researchers have pointed to other limitations such as a lack of statistical control for possible confounds including medical illness and demographics in at least one investigation (Blazer, 2004).

Possible mechanisms. As with CVAEs, several mechanisms may be postulated for antipsychotic-associated deaths, although they are all speculative. These include metabolic derangements, cardiac conduction disturbances, sedation leading to aspiration, with secondary pneumonia, and other mechanisms listed above with CVAEs.

Summary. The incidence of mortality is significantly higher with atypical antipsychotics as a group (and that of CVAEs with several agents in this class) than with placebo in patients with dementia, based on large-scale RCTs. However, several aspects of this association remain unknown.

ALTERNATIVES TO ANTIPSYCHOTICS IN DEMENTIA PATIENTS

The alternatives to antipsychotics for treating psychosis and agitation in persons with dementia include no treatment,

use of other psychotropic drugs, and psychosocial and psychotherapeutic interventions. The consequences of these options are considered below.

No Specific Treatment

Not initiating any specific treatment may be a viable option in mild-to-moderate cases, or if symptoms are not overtly disturbing for the patient and are not resulting in impaired functioning. However, serious consequences are generally associated with persistent or severe psychosis and agitation in persons with dementia that may make nonspecific treatment impractical and even dangerous in certain cases.

Other Psychotropics

Psychotropics from other medication classes have been proposed for treating psychosis and agitation in dementia (Sink *et al*, 2005). Compared with antipsychotics, even less evidence base exists regarding the use of non-antipsychotic medications for these symptoms. We searched PubMed through November 1, 2006 for RCTs of non-antipsychotic medications primarily targeted at psychosis or agitation associated with AD or dementia in general. We used the following search terms combined with 'dementia' and limited to 'clinical trials': citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, tricyclic, bupropion, duloxetine, mirtazapine, moclobemide, nefazodone, reboxetine, trazodone, venlafaxine, carbamazepine, divalproex, gabapentin, lamotrigine, phenytoin, topiramate, valproic acid, lithium, benzodiazepine, alprazolam, clonazepam, diazepam, lorazepam, oxazepam, buspirone, donepezil, galantamine, rivastigmine, tacrine, memantine, propranolol, and estrogen. Additionally, we searched 'dementia and agitation', 'dementia and psychosis', and 'dementia and aggression' with a limit of 'randomized controlled trials'. Table 1 summarizes the studies ($n = 17$), we found, that were explicitly designed to assess efficacy for psychosis and/or agitation, and included 20 or more subjects. Many trials had important methodological limitations (eg small sample sizes). Overall, these trials yielded, at best, mixed results regarding therapeutic efficacy and tolerability.

Cholinesterase inhibitors and memantine have been reported to have small-to-medium effect size effects on neuropsychiatric symptoms, including psychosis and agitation; however, these data were obtained from secondary outcome measures and *post hoc* analyses of patients who often did not have clinically significant behavioral symptoms at baseline, and yet other trials have shown no effect of cognitive enhancers on behavior (Cummings *et al*, 2006a, b; Sink *et al*, 2005; McKeith *et al*, 2000; Trinh *et al*, 2003; Hermann *et al*, 2005). A prospective trial of donepezil for neuropsychiatric symptoms in outpatients with mild-moderate AD showed improvement in global neuropsychiatric symptoms during open-label treatment for 3 months, followed by symptomatic worsening only in placebo-treated patients during the subsequent randomized discontinuation phase of the trial (Holmes *et al*, 2004). Yet, these patients had relatively modest levels of behavioral symptoms. A recent placebo-controlled RCT of donepezil, the British Medical Research Council-sponsored CALM-AD trial,

showed no effect of donepezil on behavior in AD patients with both severe dementia and substantial behavioral symptoms (Howard R, unpublished data). One small RCT compared quetiapine, rivastigmine, and placebo specifically to assess efficacy for agitation in dementia patients, and found no difference among the treatment groups (Ballard *et al*, 2005).

As with antipsychotics, no other psychotropic medications have been approved by the FDA for the treatment of psychosis or agitation in dementia. Nonetheless, some of these agents may be considered on a case-by-case basis, taking into account the risk-benefit ratio for each individual patient. There is a paucity of clinical trials with psychotropics in older adults in general and in dementia patients in particular, with consequent lack of evidence-based therapeutic alternatives. Several factors contribute to this dearth of clinical trials in older adults—for example, pharmaceutical companies tend to shy away from studying older adults because of their increased medical comorbidity, polypharmacy, cognitive deficits, and a greater risk for most side effects (Roose and Sackeim, 2002; Ownby, 2001; Schneider *et al*, 2003).

Psychosocial and Psychotherapeutic Interventions

In the RCTs of antipsychotics in patients with dementia summarized earlier, the placebo response rate was generally 30–50%. This relatively high placebo response rate may be attributed, in part, to nonspecific therapeutic factors such as improved attention and care for patients enrolled in clinical trials, suggesting a possible value of psychosocial and behavioral treatments for this patient population. Clinical experience as well as several small studies support the usefulness of specific interventions of this type in individual patients. Unfortunately, the evidence base for the efficacy of most psychosocial interventions in dementia patients is limited (Cohen-Mansfield, 2001; Livingston *et al*, 2005). Livingston *et al* (2005) recently reviewed psychosocial treatment trials for neuropsychiatric symptoms of dementia and noted several promising treatments (eg cognitive stimulation therapy, behavioral management techniques, music therapy, caregiver education). However, only nine of 162 studies included in the review were graded as 'level 1 evidence' using guidelines from the Oxford Centre for Evidence-Based Medicine, and several studies focused on outcomes other than psychosis or agitation (eg depression). Similarly, Ayalon *et al* (2006) recently published a systematic review of nonpharmacological treatments for neuropsychiatric symptoms of dementia, and using strict inclusion criteria suggested by the American Psychological Association, found only three RCTs that met these criteria. All three RCTs evaluated caregiving interventions, and the results were inconclusive.

The published studies of psychosocial/behavioral treatments have a number of methodological limitations. Many, if not most, of the patients included in such studies had mild symptoms, so that these treatments might only be useful in mild to moderate cases. Additionally, assessments of adverse outcomes in many such trials were not as systematically conducted as in pharmaceutical trials. This leaves open a possibility that adverse effects might not have been adequately evaluated and reported. Despite these

Table 1 Randomized Controlled Trials Using Non-Antipsychotic Medications for Psychosis and/or Agitation in Persons with Dementia

Authors (year)	Psychotropic (daily dose)	Sample (n)	Outcome measure	Results	Comments
<i>Antidepressants</i>					
Sultzer et al (1997)	Trazodone (50–250 mg)	Inpatients with dementia and agitation or aggression (28)	CMAI, OAS, CGI	Trazodone = haloperidol (1–5 mg/day); trazodone better tolerated than haloperidol	Small sample size; heterogeneous dementia etiologies included; no PBO control group; chloral hydrate as rescue med
Teri et al (2000)	Trazodone (50–300 mg)	AD patients with agitation (149)	ADCS-CGIC	Trazodone = PBO on efficacy and side effects	4-armed trial (including PBO, haloperidol, and cognitive behavioral therapy management) failed to distinguish among any treatment group; heterogeneous target symptoms
Levkovitz et al (2001)	Fluoxetine (50 mg)	AD patients with psychosis concomitantly treated with perphenazine 12 mg/day (20)	BPRS, CGI	Perphenazine+fluoxetine better than perphenazine+PBO on total BPRS only	No change in positive symptoms with fluoxetine augmentation; small sample; fluoxetine can increase antipsychotic blood levels; little description of concomitant meds or adverse events; crossover design could cause SSRI withdrawal to confound observations; fixed, low dose for brief duration
Pollock et al (2002)	Citalopram (20 mg)	Inpatients with dementia-associated psychosis and/or agitation/aggression (85)	Neuro-behavioral Rating Scale	Citalopram better than PBO for total score and liability+agitation subscales; citalopram = PBO for tolerability	Modest sample size; heterogeneous target symptoms; heterogeneous dementia etiologies; lorazepam as rescue med; relatively high attrition in severely ill population; third arm treated with perphenazine, which did not differ from citalopram or PBO
Lancot et al (2002)	Sertraline (100 mg)	Institutionalized persons with severe AD with NPI score > 7 but without major depression (22)	NPI, CMAI, BEHAVE-AD, CGI	Sertraline = PBO on efficacy and tolerability	Small sample size; limited rescue med with lorazepam; higher prolactin response to fenfluramine challenge somewhat predictive of better response to sertraline
Finkel et al (2004)	Sertraline (50–200mg)	AD patients with NPI score > 5, taking donepezil 10 mg/day (276)	NPI, CGI, BEHAVE-AD	Sertraline = PBO; more diarrhea in sertraline group	Heterogeneous target symptoms; 8-week open treatment with donepezil as lead-in to sertraline trial could have influenced behavioral symptoms; large sample size and relatively long treatment duration (12 weeks)
<i>Anticonvulsants</i>					
Tariot et al (1998)	Carbamazepine (CBZ) (mean = 304 mg)	Dementia patients with agitation in nursing homes (51)	BPRS, CGI	CBZ better than PBO; more side effects (eg ataxia, disorientation) with CBZ	Small sample size; vascular, Alzheimer's, and mixed dementias included; chloral hydrate as rescue med; CBZ dose adjusted by non-blinded physician; some baseline differences between treatment groups
Olin et al (2001)	Carbamazepine (CBZ) (400 mg)	Dementia patients with agitation unresponsive to antipsychotics (21)	BPRS, CGI	CBZ better than PBO but trend for worsened hallucinations with CBZ	Small sample size; chloral hydrate as rescue medication; average CBZ level = 4.9 µg/ml
Porsteinsson et al (2001)	Divalproex (mean = 826 mg)	Dementia patients with agitation in nursing homes (56)	BPRS, CGI	Divalproex = PBO	Modest sample size; average VPA level = 45 µg/ml; multiple dementia diagnoses included; VPA dose adjusted by non-blinded physician
Sival et al (2001)	Valproate (VPA) (480 mg)	Dementia patients with aggression (42)	SDAS-9, CGI	VPA = PBO	Any dementia type included; secondary beneficial effects on restless/anxious behaviors noted for VPA but with multiple comparisons; treatment duration only 3 weeks
Tariot et al (2005)	Divalproex (mean = 800mg)	AD patients with agitation in nursing homes (153)	BPRS (agitation)	Divalproex = PBO	Relatively large sample size with adequate power; average VPA level (52.8 µg/ml); VPA-treated patients had more diarrhea and 'nervous system' side effects; lorazepam and zolpidem allowed as rescue meds
<i>Other</i>					
Coccaro et al (1990)	Oxazepam (10–60 mg) Diphenhydramine (25–200 mg)	Dementia patients with agitation in long-term care facilities (59)	BPRS	Oxazepam, haloperidol, and diphenhydramine were all equivalent	No placebo control; limited assessment of adverse effects; diphenhydramine now often listed among medications to avoid in the elderly because of anticholinergic effects; heterogeneous dementia population
Camillon et al (1996)	Buspirone (mean 1.5 mg)	AD patients with agitation/aggression living in a nursing home (26)	BPRS	Buspirone = haloperidol	No placebo comparison; small sample; no concomitant psychotropics except benzotropine

Table 1 Continued

Authors (year)	Psychotropic (daily dose)	Sample (n)	Outcome measure	Results	Comments
Christensen and Benfield (1998)	Alprazolam (1 mg)	Dementia patients with agitation living in nursing homes (48)	CGI, SCAG	Alprazolam = haloperidol	Entry criterion was treatment with haloperidol at 1 mg/day or less (not specific symptomatology); crossover design may create drug withdrawal effects
Ballard <i>et al</i> (2005)	Rivastigmine ^a (9–12 mg)	AD patients with agitation in long-term care facilities (93)	CMAI	Rivastigmine = PBO	Third treatment arm of quetiapine also failed to separate from PBO or rivastigmine; modest sample size; quetiapine may have worsened cognition
Hall <i>et al</i> (2005)	Transdermal estrogen (50–100 µg)	Male dementia patients with aggressive behaviors (27)	RAGE	Estrogen = PBO	Small sample size; 'rebound' worsening when estrogen withdrawn; adverse effects of hormonal treatments may occur over longer term; concomitant antipsychotic and benzodiazepine treatment allowed
Peskind <i>et al</i> (2005)	Propranolol (mean = 106 mg)	AD patients with agitation (31)	NPI, CGI	Propranolol better than PBO	Small sample size; effects not maintained at 6-month open-label follow-up; participants on average were on two other psychotropics during study

AD, Alzheimer disease; ADCS-CGIC, Alzheimer's Disease Cooperative Study Clinical Global Impression of Change; BEHAVE-AD, Behavioral Pathology in Alzheimer's Disease Rating Scale; BPRS, Brief Psychiatric Rating Scale; CBZ, carbamazepine; CGI, Clinical Global Impression; CMAI, Cohen-Mansfield Agitation Inventory; NPI, Neuropsychiatric Inventory; OAS, Overt Aggression Scale; PBO, placebo; RAGE, Rating Scale for Aggressive Behavior in the Elderly; SCAG, Sandoz Clinical Assessment Geriatric scale; SDAS-9, Social Dysfunction and Aggression Scale-9; VPA, valproic acid.

^aWe did not include most published trials of cholinesterase inhibitors and memantine that reported behavioral effects, because these trials were designed primarily to assess cognition, with only secondary *post hoc* analysis of behavioral symptoms.

limitations, it should be emphasized that lack of evidence is not the same as evidence of lack of efficacy for psychosocial treatments in dementia-related psychosis and agitation. An individualized approach to psychosocial treatments using behavioral and other strategies may be a reasonable choice for certain patients with these symptoms.

There is clearly a need for conducting well-designed RCTs of behavioral and psychosocial interventions in patients with dementia. It is true that there would be obstacles to widespread implementation of even evidence-based psychosocial and psychotherapeutic treatments, including a lack of financial resources, the increased training and time necessary to implement them, and a lack of reimbursement for providing them. Nonetheless, there is some limited evidence that certain psychosocial interventions can be successfully implemented. For instance, Ray *et al* (1993) demonstrated that a comprehensive program to reduce antipsychotic drug use through education of physicians, nurses, and other nursing home staff was effective in two rural community nursing homes. The number of days of antipsychotic use decreased by 72% in the education homes compared with 13% in the control homes ($p < 0.001$). A more recent study demonstrated that a training and support intervention delivered to nursing home staff decreased the use of antipsychotics (Fossey *et al*, 2006). Additionally, collaborative care management in primary care settings, when compared with augmented usual care, showed improvements in overall severity of neuropsychiatric symptoms (Callahan *et al*, 2006). Thus, possible problems in dissemination and implementation should not stand in the way of carrying out methodologically sound RCTs of nonpharmacological interventions in patients with dementia.

Summary

The efficacy and safety of pharmacological and psychosocial/behavioral treatment alternatives to antipsychotics for managing patients with dementia complicated by psychosis and/or agitation remain unclear.

SUMMARY OF WHAT IS KNOWN AND WHAT IS NOT KNOWN REGARDING ANTIPSYCHOTICS FOR PSYCHOSIS AND AGITATION IN PATIENTS WITH DEMENTIA

The following is a summary of what is known and what is not regarding the use of antipsychotic drugs in dementia-associated psychosis and agitation, based largely on the literature discussed above.

What is Known

- (1) Psychosis, aggression, and agitation are common problems in patients with dementia, and when severe or persistent, can cause considerable patient distress and disability, as well as caregiver strain and early institutionalization.
- (2) There is no FDA-approved indication for a drug to treat psychosis or agitation in persons with dementia. However, unlabeled (or 'off-label') use of pharmacotherapy, especially antipsychotics, is common practice.

- (3) More RCTs have been carried out in dementia patients with psychosis and/or agitation for atypical antipsychotics (aripiprazole, olanzapine, quetiapine, and risperidone) and for haloperidol than for other classes of psychotropic drugs. Most of these trials have included patients with AD or dementia of unspecified etiology. The RCTs examining antipsychotics for agitation and/or psychosis associated with dementia, in aggregate, suggest modest efficacy in symptom reduction with active treatment compared with placebo. However, several individual trials have yielded negative results. The recent CATIE-AD trial suggested that side effect burden may negate the clinical effectiveness of these agents.
- (4) The incidence of mortality is significantly higher with atypical antipsychotics as a group (and that of CVAEs with several agents in this class) than with placebo in patients with dementia, based on large-scale RCTs. This has prompted the addition of an FDA black-box warning regarding these risks to the prescribing information for atypical antipsychotics. The overall risk difference is 1–2% over 8–12 weeks. These risks in addition to acute and subacute adverse effects such as excessive sedation, postural hypotension, and falls should be taken into account when considering treatment.
- (5) Atypical antipsychotics are less likely than most first generation antipsychotics (especially haloperidol) to cause or exacerbate EPS and tardive dyskinesia in dementia patients. However, no other differences in efficacy or safety have been demonstrated between typical and atypical agents, although typical antipsychotics are less expensive. Individual typical or atypical drugs may have less propensity to cause certain side effects (eg anticholinergic, hypotensive, metabolic) compared with certain other individual agents in specific patients.
- (6) The placebo response rate in RCTs testing antipsychotics in dementia is relatively high (generally 30–40%). Nonspecific therapeutic factors such as improved attention and care for patients enrolled in clinical trials likely account for a substantial portion of this improvement.

What is Unknown

- (1) Direct comparisons of typical and atypical antipsychotics in controlled trials in persons with dementia have been limited. As such, differential effects of these medication classes on symptom improvement and various adverse reactions (including CVAEs and death) remain undetermined. Likewise, individual antipsychotics within the same class may have differences in serious side effect profiles, but head-to-head comparisons among atypical antipsychotics have been uncommon.
- (2) Given the relatively brief duration of most RCTs, the risks for CVAEs and death beyond 8–12 weeks are unknown, as are any potential long-term benefits from continued antipsychotic treatment.
- (3) No specific risk or protective factors related to antipsychotic-associated CVAEs or deaths are known.

It is possible that as-yet undetermined factors (eg medical comorbidity, etiology or stage of dementia, concomitant medications, antipsychotic dose, genetic factors) mediate risks in individual patients. The same is true regarding possible mediators/moderators of therapeutic effects.

- (4) The efficacy and safety of treatment alternatives to antipsychotics are unclear. No psychotropic drug has well-established efficacy and safety in patients with dementia complicated by agitation or psychosis. The same is true for psychosocial interventions.
- (5) The behavioral effects of treatments for dementia targeted at cognitive symptoms (ie cholinesterase inhibitors and memantine) are unclear, but appear to be modest at best, based on existing data.
- (6) Whereas advances have been made in understanding the neurobiology of psychiatric complications of dementia, these findings have not yet established the most proximal causes of these symptoms. As such, specifically targeted pharmacotherapies for psychosis and agitation in dementia are unavailable; current treatments are primarily an extrapolation of treatments for related but somewhat different syndromes (eg schizophrenia). Future treatments, more specific to underlying pathological processes in dementia, may yield better results.

CLINICAL AND RESEARCH RECOMMENDATIONS

Clinical Recommendations

- (1) Determining etiology of symptoms: psychosis or agitation may result from multiple causes in people with dementia. Seeking to identify the underlying causative factors for the symptoms in a given individual should be the first step in management. For example, these symptoms may be a part of a delirium secondary to anticholinergic toxicity; in such cases, reducing the anticholinergic load would be warranted. Likewise, agitation may be a result of psychosocial stressors that may be correctable.
- (2) General therapeutic considerations: good clinical care, independently from pharmacotherapy, may be helpful for patients with dementia-related psychosis and/or agitation, and their caregivers, through nonspecific and specific interventions. Nonspecific interventions such as empathy and attention to interpersonal and social issues may be particularly helpful, as evidenced in several studies and by the improvements in the placebo groups in nearly all clinical trials. Specific interventions include environmental, psychosocial, behavioral, and medical interventions to reduce or mitigate possible antecedents as well as consequences of the behaviors.
- (3) Shared decision making: clinicians and their patients should make decisions based on the patients' and families' values regarding quality of life goals. Providers should engage caregivers, family members, and patients (whenever possible), in the decision-making process for treating psychosis, agitation, and other disruptive behaviors. This will include offering appropriate information about what is known regarding

overall risks and benefits of different treatment options. Such information should be tailored to the educational/intellectual level of the recipient, and also respect the individual's desire for autonomy in medical decisions. Thus, some people may want to fully engage in a detailed risk/benefit analysis, and be equal partners in treatment decisions. Others may be more deferential to the clinician out of habit or anxiety about making a wrong decision, but even these individuals should be provided with all relevant information (including risks and benefits of no treatment and of possible environmental/psychosocial interventions) along with opportunities to participate in decisions to the extent they are comfortable. Clinicians should document the fact that a discussion of these issues was conducted.

- (4) Identifying target symptoms: it is important to identify target signs and symptoms, and to establish a time frame in which to expect and evaluate an intervention's effectiveness and in which to decide on continuing or altering treatment. Both expert clinical opinion and RCT evidence demonstrate that a sizable proportion of both drug- and placebo-treated patients improve within 2–4 weeks.
- (5) Choice of pharmacotherapy: not all psychotic symptoms or agitations need pharmacotherapy. Only severe symptoms that are persistent or recurrent and cause clinically significant functional disruption would generally be considered appropriate for ongoing pharmacologic management. At this time, there is no single treatment algorithm that can be routinely recommended for all patients with dementia. Individual patients may tolerate and benefit from antipsychotic medications such that their use in patients with severe and persistent or recurrent symptoms may be justified, but these medications are not an unequivocal first-line treatment. Use of antipsychotics after shared decision making with patients and/or caregivers and followed by close clinical monitoring is within the realm of reasonable practice. There is no evidence to support overall better safety profiles with typical (compared with atypical) antipsychotics, and these drugs, as a class, may not be considered as therapeutic alternatives for the purpose of minimizing these risks (although there may be individual exceptions). There is a lack of evidence to support efficacy or safety when other agents (eg antidepressants, anticonvulsants, benzodiazepines) are used for treating psychosis or agitation in people with dementia.
- (6) Dosages: one should use the lowest medication dosages required and for the shortest time period necessary. This may include medication tapering or discontinuation in patients who have symptomatic remission. An examination of therapeutic and adverse effects of these medications in elderly persons with dementia suggests target doses of 0.5–1.5 mg/day of risperidone; 5–10 mg/day of olanzapine; 50–200 mg/day of quetiapine; and 7–12 mg/day of aripiprazole, although these dose ranges are not universally considered as evidence-based (Katz *et al*, 1999; Alexopoulos *et al*, 2005; Jeste *et al*, 1999a,b; Zhong *et al*, 2007; Street *et al*, 2000; De Deyn *et al*, 2005; Tariot *et al*, 2006).
- (7) Monitoring effectiveness: the clinician should regularly assess treatment response in terms of effectiveness. Although a number of instruments for evaluating clinical outcomes associated with neuropsychiatric symptoms in dementia have been used in research, these have not generally been shown to be feasible or useful tools for everyday clinical practice. Several recent reviews have summarized the relative strengths and weaknesses of scales designed to measure such outcomes in studies of dementia (Rockwood, 2007; Ready and Ott, 2003; De Deyn and Wirshing, 2001). Individual clinicians should consider the following domains in monitoring treatment effectiveness: symptom severity and frequency, daily functioning, quality of life, and global impressions of clinicians, caregivers, and (when possible) patients.
- (8) Monitoring safety: elderly persons with dementia constitute a fragile population in whom introduction of any prescription medication may carry some appreciable risks. Treatment approaches should, therefore, be frequently reassessed. The clinician should regularly monitor relevant adverse effects of antipsychotics, including EPS, tardive dyskinesia, blood pressure, body weight, and blood glucose and lipid levels. The physical assessments may be conducted at baseline and then every 3 months, whereas the lab testing may be carried out at baseline, months 3 and 6 and every 6 months thereafter. These are general recommendations, and the exact intervals may be shorter or longer depending on an individual patient's medical profile. Additional medical evaluations may be needed for patients with specific risk factors.
- (9) Education of patients and caregivers: in addition to the information regarding risks/benefits discussed during the informed consent process, it is necessary to educate patients, caregivers, and family members about actions to take if and when side effects occur. Also the clinician should assess the caregivers' ability to monitor beneficial and adverse effects of the treatment plan, including medication initiation and withdrawal.
- (10) Considering discontinuing or switching pharmacotherapy: absence of significant improvement in target symptoms or occurrence of certain adverse effects (eg weight gain, hyperglycemia, tardive dyskinesia) may warrant considerations for discontinuation of medication or switching to another treatment with a putatively safer profile for the particular side effects.
- (11) Given the complex array of medical illnesses typical of such patients, physicians should coordinate patient care with other health-care professionals (especially, primary care physicians) to minimize risks of treatments.

In view of limited empirical evidence to guide many clinical decisions, clinicians will often have to make choices based on their clinical experience and judgment. The serious consequences of psychosis and agitation in dementia, the problematic risk-benefit profile of antipsychotic medications for such symptoms, and the paucity of data on other treatment alternatives combine to create a clinical conundrum for which there are no immediate or simple solutions.

Research Recommendations

There is an urgent need for additional research in this area of considerable public health significance. Below we list some examples of suggested research.

- (1) Patient-level meta-analyses of existing data from clinical trials so as to identify predictors of efficacy as well as factors related to increased risk of CVAEs and death in sub-populations of patients and with specific aspects of treatment (eg lower vs higher doses).
- (2) Establishing clinically significant treatment outcomes and goals from the perspectives of patients and caregivers—for example via qualitative studies.
- (3) Exploring biological mechanisms (including non-dopaminergic ones) underlying psychosis and agitation in dementia, and using such data to continually refine these diagnostic constructs/phenotypes.
- (4) Search for biomarkers that may allow risk/benefit prediction on an individualized level (eg genetic markers related to neurotransmitters or vascular risk factors; functional neuroimaging).
- (5) Development and testing of novel pharmacological targets (pharmacological agents that more directly affect underlying pathophysiologic changes) for psychosis and agitation in dementia, including neuroprotective agents; in light of the recent safety concerns, much needed research to discover effective treatments for these syndromes may not be undertaken by pharmaceutical industry.
- (6) Studies of mechanism of action for antipsychotic effects on cardio/cerebrovascular systems.
- (7) Exploring effects of nonpharmacological somatic treatments for psychosis and agitation in dementia (eg light therapy, electroconvulsive therapy, transcranial magnetic stimulation).
- (8) Conducting additional trials of psychosocial treatments for dementia-related neuropsychiatric symptoms.
- (9) Research on the shared decision-making process and its effects on consumer satisfaction in this clinical setting.
- (10) Investigations with a focus on delaying or preventing the emergence of psychosis and agitation in persons with dementia.

POTENTIAL CONFLICTS OF INTEREST DISCLOSURES FOR THE MEMBERS OF THE ACNP TASK FORCE ON ANTIPSYCHOTICS IN THE ELDERLY

Dilip V Jeste

Financial involvement:

Consultant—Bristol-Myers Squibb, Janssen Pharmaceuticals, Otsuka Pharmaceuticals, and Solvay/Wyeth Pharmaceuticals.

Grants:

National Institute of Mental Health, and National Institute on Aging.

Astra Zeneca, Bristol-Myers Squibb, Eli Lilly & Company, and Janssen Pharmaceuticals donate antipsychotic medication to NIMH-funded R01 titled ‘Metabolic Effects of Newer Antipsychotics in Older Patients.’

Janssen Pharmaceuticals has provided an unrestricted educational grant to the University of California Regents to supplement NIMH-funded R25 titled ‘Summer Research Institute in Geriatric Psychiatry.’

Dan Blazer

Financial involvement:

Belvoir Publishing, PSYCHCME, Hartford Foundation, and RAND.

Grants:

NIMH T32, NIDA Data & Statistical Coordinating Center, and Clinical Trials Network.

Daniel E Casey

Financial involvement:

Consultant and Speakers Bureau—Abbott Laboratories, Bristol-Myers Squibb, Janssen Pharmaceuticals, and Pfizer Inc.

Consultant—NuPathe Inc., Solvay Pharmaceuticals, Sumitomo Pharmaceuticals, and Wyeth Pharmaceuticals.

Thomas Meeks

Financial involvement:

None.

Grants:

NARSAD.

Carl Salzman

Grants:

Bristol-Myers Squibb and Otsuka Pharmaceuticals.

Lon Schneider

Financial involvement:

Compensation or honoraria from Astra Zeneca, Bristol-Myers Squibb, Johnson and Johnson, and Eli Lilly, all manufacturers of drugs mentioned in this work.

Grants:

NIH NO1 MH9001, 5 P50 AG005142, and the State of California Alzheimer’s Disease Research Program.

Pierre Tariot

Financial involvement:

Compensation or honoraria from Abbott, Astra Zeneca, Bristol-Myers Squibb, Eisai, Forest, Johnson and Johnson, and Pfizer, and research support from these companies as well as Eli Lilly, all manufacturers of drugs mentioned in this work.

Grants:

NIA, NIMH, Alzheimer's Association, Arizona Dept. of Health Services, Institute for Mental Health Research.

Kristine Yaffe**Financial involvement:**

Consultant and Grants—Pfizer and Wyeth.

Grants:

NIH, NIA, NARSAD, NIMH, NIDDK, and Anonymous Foundation.

REFERENCES

- Aarsland D, Bronnick K, Ehrst U, De Deyn PP, Tekin S, Emre M *et al* (2007). Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. *J Neurol Neurosurg Psychiatry* 78: 36–42.
- Abilify prescribing information (2006). http://www.bms.com/cgi-bin/anybin.pl?sql=select%20PPI%20from%20TB_PRODUCT_PPI%20where%20PPI_SEQ=101&key=PPI, accessed October 20, 2006.
- Alexopoulos GS, Schultz SK, Lebowitz BD (2005). Late-life depression: a model for mechanism-based classification. DSM-V White paper. *Biol Psychiatry* 58: 283–289.
- Allen RS, Burgio LD, Fisher SE, Michael Hardin J, Shuster JL (2005). Behavioral characteristics of agitated nursing home residents with dementia at the end of life. *Gerontologist* 45: 661–666.
- Ayalon L, Gum AM, Feliciano L, Areal PA (2006). Effectiveness of nonpharmacological interventions for the management of neuropsychiatric symptoms in patients with dementia: a systematic review. *Arch Intern Med* 166: 2182–2188.
- Ballard C, Margallo-Lana M, Juszcak E, Douglas S, Swann A, Thomas A *et al* (2005). Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. *BMJ* 330: 874.
- Ballard C, Waite J (2006). The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. *Cochrane Database Syst Rev* 1: CD003476.
- Banerjee S, Smith SC, Lamping DL, Harwood RH, Foley B, Smith P *et al* (2006). Quality of life in dementia: more than just cognition. An analysis of associations with quality of life in dementia. *J Neurol Neurosurg Psychiatry* 77: 146–148.
- Bech P, Larsen JK, Andersen J (1988). The BPRS: psychometric developments. *Psychopharmacol Bull* 24: 118–121.
- Blazer DG (2004). Comment on Nasrallah *et al*: lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol. *Am J Geriatr Psychiatry* 12: 658–659.
- Bowen JD, Malter AD, Sheppard L, Kukull WA, McCormick WC, Teri L *et al* (1996). Predictors of mortality in patients diagnosed with probable Alzheimer's disease. *Neurology* 47: 433–439.
- Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R *et al* (2003). A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. *J Clin Psychiatry* 64: 134–143.
- Brodaty H, Low LF (2003). Aggression in the elderly. *J Clin Psychiatry* 64: 36–43.
- Buhr GT, Kuchibhatla M, Clipp EC (2006). Caregivers' reasons for nursing home placement: clues for improving discussions with families prior to the transition. *Gerontologist* 46: 52–61.
- Callahan CM, Boustani MA, Unverzagt FW, Austrom MG, Damush TM, Perkins AJ *et al* (2006). Effectiveness of collaborative care for older adults with Alzheimer disease in primary care: a randomized controlled trial. *J Am Med Assoc* 295: 2148–2157.
- Cantillon M, Brunswick R, Molina D, Bahro M (1996). Buspirone vs haloperidol: a double-blind trial for agitation in a nursing home population with Alzheimer's disease. *Am J Geriatr Psychiatry* 4: 263–267.
- Chan WC, Lam LC, Choy CN, Leung VP, Li SW, Chiu HF (2001). A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. *Int J Geriatr Psychiatry* 16: 1156–1162.
- Christensen DB, Benfield WR (1998). Alprazolam as an alternative to low-dose haloperidol in older, cognitively impaired nursing facility patients. *J Am Geriatr Soc* 46: 620–625.
- Coccaro EF, Kramer E, Zemishlany Z, Thorne A, Rice III MC, Giordani B *et al* (1990). Pharmacologic treatment of noncognitive behavioral disturbances in elderly demented patients. *Am J Psychiatry* 147: 1640–1645.
- Cohen-Mansfield J (2001). Nonpharmacologic interventions for inappropriate behaviors in dementia: a review and critique. *Am J Geriatr Psychiatry* 9: 361–381.
- Cummings JL (1997). The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. *Neurology* 5: S10–S16.
- Cummings JL, McRae T, Zhang R, Donepezil-Sertraline Study Group (2006a). Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. *Am J Geriatr Psychiatry* 14: 605–612.
- Cummings JL, Schneider E, Tariot PN, Graham SM, Memantine MEM-MD-02 Study Group (2006b). Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. *Neurology* 67: 57–63.
- De Deyn P, Jeste DV, Swanink R, Kostic D, Breder C (2005). Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study. *J Clin Psychopharmacol* 25: 463–467.
- De Deyn P, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PLJ, Eriksson S *et al* (1999). A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. *Neurology* 53: 946–955.
- De Deyn PP, Wirshing WC (2001). Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia. *J Clin Psychiatry* 62: 19–22.
- Dolder CR, Jeste DV (2003). Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients. *Biol Psychiatry* 53: 1142–1145.
- Donaldson C, Tarrier N, Burns A (1998). Determinants of carer stress in Alzheimer's Disease. *Int J Geriatr Psychiatry* 13: 248–256.
- Drevets WC, Rubin EH (1989). Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type. *Biol Psychiatry* 25: 39–48.
- Evans DA, Funkenstein H, Albert MS, Scherr PA, Cook NR, Chown MJ *et al* (1989). Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. *J Am Med Assoc* 262: 2551–2556.
- Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M *et al* (2005). Global prevalence of dementia: a Delphi consensus study. *Lancet* 366: 2112–2117.
- Finkel SI, Mintzer JE, Dysken M, Krishnan KRR, Burt T, McRae T (2004). A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. *Int J Geriatr Psychiatry* 19: 9–18.
- Fossey J, Ballard C, Juszcak E, James I, Alder N, Jacoby R *et al* (2006). Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. *BMJ* 332: 756–761.

- Fuh JL, Liu CK, Mega MS, Wang SJ, Cummings JL (2001). Behavioral disorders and caregivers' reaction in Taiwanese patients with Alzheimer's disease. *Int Psychogeriatr* 13: 121–128.
- Gill SS, Rochon PA, Herrmann N, Lee PE, Sykora K, Gunraj N et al (2005). Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. *BMJ* 330: 445.
- Glazer WM (2000). Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. *J Clin Psychiatry* 61: 16–21.
- Hall KA, Keks NA, O'Connor DW (2005). Transdermal estrogen patches for aggressive behavior in male patients with dementia: a randomized, controlled trial. *Int Psychogeriatr* 17: 165–178.
- Herrmann N, Rabheru K, Wang J, Binder C (2005). Galantamine treatment of problematic behavior in Alzheimer disease: *post-hoc* analysis of pooled data from three large trials. *Am J Geriatr Psychiatry* 13: 527–534.
- Herrmann N, Lanctot KL (2005). Do atypical antipsychotics cause stroke? *CNS Drugs* 19: 91–103.
- Herrmann N, Mamdani M, Lanctot KL (2004). Atypical antipsychotics and risk of cerebrovascular accidents. *Am J Psychiatry* 161: 1113–1115.
- Holmes C, Wilkinson D, Dean C, Vethanayagam S, Olivieri S, Langley A et al (2004). The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. *Neurology* 63: 214–219.
- Jeste DV (2000). Tardive dyskinesia in older patients. *J Clin Psychiatry* 61: 27–32.
- Jeste DV, Finkel SI (2000). Psychosis of Alzheimer's Disease and related dementias: diagnostic criteria for a distinct syndrome. *Am J Geriatr Psychiatry* 8: 29–34.
- Jeste DV, Lacro JP, Bailey A, Rockwell E, Harris MJ, Caligiuri MP (1999a). Incidence of tardive dyskinesia with risperidone versus haloperidol. *J Am Geriatr Society* 47: 716–719.
- Jeste DV, Meeks TW, Kim DS, Zubenko GS (2006). Research agenda for DSM-V: diagnostic categories and criteria for neuropsychiatry syndromes in dementia. *J Geriatr Psychiatry Neurol* 19: 160–171.
- Jeste DV, Rockwell E, Harris MJ, Lohr JB, Lacro J (1999b). Conventional versus newer antipsychotics in elderly patients. *Am J Geriatr Psychiatry* 7: 70–76.
- Jin H, Meyer JM, Jeste DV (2004). Atypical antipsychotics and glucose dysregulation: a systematic review. *Schizophr Res* 71: 195–212.
- Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP et al (2006). Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). *Arch Gen Psychiatry* 63: 1079–1087.
- Kammoun S, Gold G, Bouras C, Giannakopoulos P, McGee W, Herrmann F et al (2000). Immediate causes of death of demented and non-demented elderly. *Acta Neurol Scand* 176: 96–99.
- Kaplan HI, Sadock BJ (1998). *Synopsis of Psychiatry*. Williams & Wilkins: Baltimore, MD.
- Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M (1999). Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial. *J Clin Psychiatry* 60: 107–115.
- Kaufer DI, Cummings JL, Christine D, Bray T, Castellon S, Masterman D et al (1998). Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the Neuropsychiatry Inventory Caregiver Distress Scale. *J Am Geriatr Soc* 46: 210–215.
- Keene J, Hope T, Fairburn CG, Jacoby R (2001). Death and dementia. *Int J Geriatr Psychiatry* 16: 969–974.
- Kindermann SS, Dolder CR, Bailey A, Katz IR, Jeste DV (2002). Pharmacologic treatment of psychosis and agitation in elderly patients with dementia: Four decades of experience. *Drugs Aging* 19: 257–276.
- Lanctot KL, Herrmann N, van Reekum R, Eryavec G, Naranjo CA (2002). Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease. *Int J Geriatr Psychiatry* 17: 531–541.
- Levkovitz Y, Bloch Y, Kaplan D, Diskin A, Abramovitch I (2001). Fluvoxamine for psychosis in Alzheimer's Disease. *J Nerv Ment Dis* 189: 126–129.
- Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al (2005). Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N Engl J Med* 353: 1209–1223.
- Livingston G, Johnston K, Katona C, Paton J, Lyketsos CG (2005). Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. *Am J Psychiatry* 162: 1996–2021.
- Lonergan E, Luxenberg J, Colford J (2001). Haloperidol for agitation in dementia. *Cochrane Database Syst Rev* 4: CD002852.
- Losonczy KG, White LR, Brock DB (1998). Prevalence and correlates of dementia: survey of the last days of life. *Public Health Rep* 113: 273–280.
- Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC (2000). Mental and behavioral disturbances in dementia: findings from the Cache County Study on memory in aging. *Am J Psychiatry* 157: 708–714.
- Matsui T, Nakaaki S, Murata Y, Sato J, Shinagawa Y, Tatsumi H et al (2006). Determinants of the quality of life in Alzheimer's disease patients as assessed by the Japanese version of the Quality of Life-Alzheimer's disease scale. *Dement Geriatr Cogn Disord* 21: 182–191.
- McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R et al (2000). Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. *Lancet* 356: 2031–2036.
- Mourik JC, Rosso SM, Niermeijer MF, Duivenvoorden HJ, Van Swieten JC, Tibben A (2004). Frontotemporal dementia: behavioral symptoms and caregiver distress. *Dement Geriatr Cogn Disord* 18: 299–306.
- Murman DL, Colenda CC (2005). The economic impact of neuropsychiatric symptoms in Alzheimer's disease: can drugs ease the burden? *Pharmacoeconomics* 23: 227–242.
- Nasrallah HA, White T, Nasrallah AT (2004). Lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol: preliminary analysis of retrospective data. *Am J Geriatr Psychiatry* 12: 437–439.
- Olin JT, Fox FS, Pawluczyk S, Taggart NA, Schneider LS (2001). A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer Disease. *Am J Geriatr Psychiatry* 9: 400–405.
- Ownby RL (2001). Clinical trials in geriatric disorders. *Curr Psychiatry Rep* 3: 11–12.
- Peskind ER, Tsuang DW, Bonner LT, Pasualy M, Riekse RG, Snowden MB et al (2005). Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: a placebo-controlled study. *Alzheimer Dis Assoc Disord* 19: 23–28.
- Pinquant M, Sorensen S (2003). Differences between caregivers and noncaregivers in psychological health and physical health: a meta-analysis. *Psychol Aging* 18: 250–267.
- Pollock BG, Mulsant BH, Rosen J, Sweet RA, Mazumdar S, Bharucha A et al (2002). Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. *Am J Psychiatry* 159: 460–465.
- Porsteinsson AP, Tariot PN, Erb R, Cox C, Smith E, Jakimovich L et al (2001). Placebo-controlled study of divalproex sodium for agitation in dementia. *Am J Geriatr Psychiatry* 9: 58–66.
- Raivio MM, Laurila JV, Strandberg TE, Tilvis RS, Pitkala KH (2007). Neither atypical nor conventional antipsychotics increase

- mortality of hospital admissions among elderly patients with dementia: a two-year prospective study. *Am J Geriatr Psychiatry* 15: 416–424.
- Ray WA, Taylor JA, Meador KG, Lichtenstein MJ, Griffin MR, Fought R et al (1993). Reducing antipsychotic drug use in nursing homes. A controlled trial of provider education. *Arch Intern Med* 153: 713–721.
- Ready RE, Ott BR (2003). Quality of Life measures for dementia. *Health Qual Life Outcomes* 1: 11.
- Reisberg B, Auer SR, Monteiro IM (1996). Behavioral pathology in Alzheimer's disease (BEHAVE-AD) rating scale. *Int Psychogeriatr* 8: 301–308.
- Ritsner M, Gibel A, Perelroyzen G, Kurs R, Jabarin M, Ratner Y (2004). Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. *J Clin Psychopharmacol* 24: 582–591.
- Rockwood K (2007). The measuring, meaning and importance of activities of daily living (ADLs) as an outcome. *Int Psychogeriatr* 19: 467–482.
- Roose SP, Sackeim HA (2002). Clinical trials in late-life depression: revisited. *Am J Geriatr Psychiatry* 10: 503–505.
- Ropacki SA, Jeste DV (2005). Epidemiology of and risk factors for psychosis of Alzheimer's disease: a review of 55 studies published from 1990 to 2003. *Am J Psychiatry* 162: 2022–2030.
- Rosen J, Zubenko GS (1991). Emergence of psychosis and depression in the longitudinal evaluation of Alzheimer's disease. *Biol Psychiatry* 29: 224–232.
- Ryu SH, Katona C, Rive B, Livingston G (2005). Persistence of and changes in neuropsychiatric symptoms in Alzheimer disease over 6 months: the LASER-AD study. *Am J Geriatr Psychiatry* 13: 976–983.
- Samson WN, van Duijn CM, Hop WC, Hofman A (1996). Clinical features and mortality in patients with early-onset Alzheimer's disease. *Eur Neurol* 36: 103–106.
- Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS (2007). Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. *Can Med Assoc J* 176: 627–632.
- Schneider LS, Dagerman K, Insel PS (2006a). Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. *Am J Geriatr Psychiatry* 14: 191–210.
- Schneider LS, Dagerman KS, Insel P (2005). Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. *J Am Med Assoc* 294: 1934–1943.
- Schneider LS, Ismail MS, Dagerman K, Davis S, Olin J, McManus D et al (2003). Clinical antipsychotic trials of intervention effectiveness (CATIE): Alzheimer's disease trial. *Schizophr Bull* 29: 57–72.
- Schneider LS, Pollock VE, Lyness SA (1990). A meta-analysis of controlled trials of neuroleptic treatment in dementia. *J Am Geriatr Soc* 38: 553–563.
- Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS et al (2006b). Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. *N Engl J Med* 355: 1525–1538.
- Schneider LS, Tariot PN, Weintraub D (2007). Author response to letter. *N Engl J Med* 356: 416–418.
- Sink KM, Holden KF, Yaffe K (2005). Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. *J Am Med Assoc* 293: 596–608.
- Sival RC, Haffmans J, Jansen PAF, Duursma SA, Eikelenboom P (2001). Sodium valproate in the treatment of aggressive behavior in patients with dementia—a randomized placebo controlled clinical trial. *Int J Geriatr Psychiatry* 17: 579–585.
- Stanniland C, Taylor D (2000). Tolerability of atypical antipsychotics. *Drug Safety* 22: 195–214.
- Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN et al (2000). Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind randomized, placebo-controlled trial The HGEU Study Group. *Arch Gen Psychiatry* 57: 968–976.
- Suh GH, Son HG, Ju YS, Jcho KH, Yeon BK, Shin YM et al (2004). A randomized, double-blind, crossover comparison of risperidone and haloperidol in Korean dementia patients with behavioral disturbances. *Am J Geriatr Psychiatry* 12: 509–516.
- Sultzer DL, Gray KF, Gunay I, Berisford MA, Mahler ME (1997). A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. *Am J Geriatr Psychiatry* 5: 6–69.
- Tariot P, Erb R, Podgorski CA, Cox C, Patel S, Jakimovich L et al (1998). Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. *Am J Psychiatry* 155: 54–61.
- Tariot PN, Raman R, Jakimovich L, Schneider L, Porsteinsson A, Thomas R et al (2005). Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial. *Am J Geriatr Psychiatry* 13: 942–949.
- Tariot PN, Schneider L, Katz IR, Mintzer JE, Street J, Copnehaver M et al (2006). Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. *Am J Geriatr Psychiatry* 14: 767–776.
- Teri L, Logsdon RG, Peskind E, Raskind M, Weiner MF, Tractenberg RE et al (2000). Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. *Neurology* 55: 1271–1278.
- Testad I, Aasland AM, Aarsland D (2007). Prevalence and correlates of disruptive behavior in patients in Norwegian nursing homes. *Int J Geriatr Psychiatry* February 26 (E-pub ahead of print).
- Tractenberg RE, Weiner MF, Patterson MB, Teri L, Thal LJ (2003). Comorbidity of psychopathological domains in community-dwelling persons with Alzheimer's Disease. *J Geriatr Psychiatry* 16: 94–99.
- Trinh NH, Hoblyn J, Mohanty S, Yaffe K (2003). Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. *J Am Med Assoc* 289: 210–216.
- Walsh J, Welch G, Larson E (1990). Survival of outpatients with Alzheimer-type dementia. *Ann Intern Med* 113: 429–434.
- Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH et al (2005). Risk of death in elderly users of conventional vs atypical antipsychotic medications. *N Engl J Med* 353: 2335–2341.
- Weiss E, Hummer M, Koller D, Ulmer H, Fleischhaker WW (2000). Off-label use of antipsychotic drugs. *J Clin Psychopharmacol* 20: 695–698.
- Wilson RS, Tang Y, Aggarwal NT, Gilley DW, McCann JJ, Bienias JL et al (2006). Hallucinations, cognitive decline, and death in Alzheimer's disease. *Neuroepidemiology* 26: 68–75.
- Wragg RE, Jeste DV (1988). Neuroleptics and alternative treatments: management of behavioral symptoms and psychosis in Alzheimer's disease and related conditions. *Psychiatr Clin North Am* 11: 195–214.
- Yaffe K, Fox P, Newcomer R, Sands L, Lindquist K, Dane K et al (2002). Patient and caregiver characteristics and nursing home placement in patients with dementia. *J Am Med Assoc* 287: 2090–2097.
- Zhong KX, Tariot PN, Mintzer J, Minkwitz MC, Devine NA (2007). Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study. *Curr Alzheimer Res* 4: 81–93.
- Zuidema SU, Derksen E, Verhey FR, Koopmans RT (2006). Prevalence of neuropsychiatric symptoms in a large sample of Dutch nursing home patients with dementia. *Int J Geriatr Psychiatry* November 29 (E-pub ahead of print).